KRAS and intrahepatic cholangiocarcinoma: [27] As iCC is molecularly heterogeneous (common mutations ARID1A, BAP1, BRAF, ERBB2 (HER2), FGFR2, IDH1/2, KRAS, MDM2, SMAD4, and TP53), there is more potential for targeted treatments [28].